OBJECTIVE: To evaluate the impact of age and comorbidity on clinical outcomes in advanced pancreatic cancer. METHODS: Consecutive 237 patients with advanced pancreatic cancer were studied. Comorbidity was scored by Charlson comorbidity index (CCI). We compared the clinical outcomes by age or comorbidity. RESULTS: Sixty-nine patients were elderly (≥75 years), and CCI was 0 in 69 patients, 1 in 98, and ≥2 in 70. Gemcitabine-based chemotherapy was administered in 183 patients and was well tolerated in both elderly group and in those with comorbidities. In a multivariate analysis, CCI, not age, was prognostic in addition to PS, distant metastasis, chemotherapy and CA19-9: the hazard ratios of CCI 1 and ≥2 were 1.25 and 1.55, compared with CCI 0 (p=0.027). CONCLUSIONS: Gemcitabine-based chemotherapy can be an effective treatment, without significant toxicity, in elderly patients. Comorbidity, not age, was prognostic in patients with advanced pancreatic cancer.
OBJECTIVE: To evaluate the impact of age and comorbidity on clinical outcomes in advanced pancreatic cancer. METHODS: Consecutive 237 patients with advanced pancreatic cancer were studied. Comorbidity was scored by Charlson comorbidity index (CCI). We compared the clinical outcomes by age or comorbidity. RESULTS: Sixty-nine patients were elderly (≥75 years), and CCI was 0 in 69 patients, 1 in 98, and ≥2 in 70. Gemcitabine-based chemotherapy was administered in 183 patients and was well tolerated in both elderly group and in those with comorbidities. In a multivariate analysis, CCI, not age, was prognostic in addition to PS, distant metastasis, chemotherapy and CA19-9: the hazard ratios of CCI 1 and ≥2 were 1.25 and 1.55, compared with CCI 0 (p=0.027). CONCLUSIONS:Gemcitabine-based chemotherapy can be an effective treatment, without significant toxicity, in elderly patients. Comorbidity, not age, was prognostic in patients with advanced pancreatic cancer.
Authors: Sophie Cai; Theodore S Hong; Saveli I Goldberg; Carlos Fernandez-del Castillo; Sarah P Thayer; Cristina R Ferrone; David P Ryan; Lawrence S Blaszkowsky; Eunice L Kwak; Christopher G Willett; Keith D Lillemoe; Andrew L Warshaw; Jennifer Y Wo Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: R S Raju; N Coburn; N Liu; J M Porter; S J Seung; M C Cheung; N Goyert; N B Leighl; J S Hoch; M E Trudeau; W K Evans; K N Dainty; C C Earle; N Mittmann Journal: Curr Oncol Date: 2015-12 Impact factor: 3.677
Authors: T Hamada; Y Nakai; H Yasunaga; H Isayama; H Matsui; N Takahara; T Sasaki; K Takagi; T Watanabe; H Yagioka; H Kogure; T Arizumi; N Yamamoto; Y Ito; K Hirano; T Tsujino; M Tada; K Koike Journal: Br J Cancer Date: 2014-03-18 Impact factor: 7.640